As an example, Mivebresib treatment was shown to reduce the protein and mRNA levels of EWSR1::ATF1 in a dose-dependent manner in clear cell sarcoma, due to the modulation of BRD4 recruitment at the EWSR1 promoter region [57]. The gene discussed is ATF1; the disease is clear cell sarcoma.